Sangamo Therapeutics expands ATM equity offering capacity by $175M to $325M total

SANGAMO THERAPEUTICS, INC

Amendment No. 2 with Jefferies LLC adds $175M in common stock to existing at-the-market program.
Prior to amendment, $115M of original $150M capacity had been sold.
Remaining capacity under amended agreement is approximately $210M (based on $325M total less $115M sold).
Terms and conditions of the Sales Agreement unchanged; shares sold at market prices under effective shelf registration.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SANGAMO THERAPEUTICS, INC amended Amendment No. 2 to the Sales Agreement with Jefferies LLC valued at up to $175 million (effective 2022-12-23).

Action: amendment
Agreement: atm program
Counterparty: Jefferies LLC
Value: up to $175 million
Effective: 2022-12-23

Exact text from the filing

On December 23, 2022, the Company and Jefferies entered into Amendment No. 2 to the Sales Agreement ("Amendment No. 2" and, together with the Sales Agreement, the "Amended Sales Agreement") to provide for an increase in the aggregate offering amount under the Sales Agreement such that the Company may offer and sell additional shares of Common Stock having an aggregate offering amount of up to $175 million

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

SANGAMO THERAPEUTICS, INC filing history →

Source: SEC EDGAR

accession 0001628280-22-032552

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.